HeartFlow FFRCT Analysis
At the intersection of health and technology, HeartFlow leverages advanced technology and applies it to healthcare. With the HeartFlow FFRCT Analysis, HeartFlow is driving towards a new standard of care for the diagnosis and management of coronary artery disease – the number one killer worldwide.
Learn more about our technology in this short video or preview the HeartFlow Analysis by downloading our mobile app (available on iOS in North America and the UK only) or clicking below.
Watch Video
Preview HeartFlow
The FISH&CHIPS Study
Real-world study reveals significant reduction in all-cause and cardiovascular mortality.
A real world, multi-center, retrospective study including more than90,000 patientsassessing at a national level the incremental impact of adding FFRCT to a CCTA-first diagnostic paradigm for evaluating and managing coronary artery disease (CAD). The study was conducted in England and was funded by UK Medical Research Council (MRC).
Download the Data Sheet
The modern way to diagnose coronary artery disease
+
The path to diagnosing coronary artery disease (CAD) hasn’t always been clear or reliable.1,2 Until now. The pathway begins with a CCTA. If the physician sees disease, the CCTA images are sent to HeartFlow, where AI algorithms, computational fluid dynamics and trained analysts create the HeartFlow FFRCT Analysis. This personalized, color-coded 3-D model of a patient’s coronary arteries provides functional information about each blockage.
The modern way to diagnose coronary artery disease
+
The path to diagnosing coronary artery disease (CAD) hasn’t always been clear or reliable.1,2 Until now. The pathway begins with a CCTA. If the physician sees disease, the CCTA images are sent to HeartFlow, where AI algorithms, computational fluid dynamics and trained analysts create the HeartFlow FFRCTAnalysis. This personalized, color-coded 3-D model of a patient’s coronary arteries provides functional information about each blockage.
How do non-invasive CAD tests compare?
HeartFlow One Pathway
| SPECT | Stress Echo | Coronary CTA | HeartFlow Analysis | |
|---|---|---|---|---|
Common Questions |
|
|
|
|
Does my patient have CAD? | X | X | X | X |
Do the vessels have plaque? | X | X | ||
Where are the coronary artery specific stenoses? | X | X | ||
Is there possible ischemia? | X | X | X | |
What are the lesion-specific functional limitations? | X | |||
Which vessels may benefit from PCI/CABG/OMT? | X | |||
Is prognostic information provided? | X | X | X | X |
Diagnostic Performance* |
|
|
|
|
Disadvantages1, 2-6 | Low sensitivity; high rate of false negatives; higher radiation exposure; lacks anatomic data | Often requires additional testing; lacks anatomic data | High sensitivity can lead to overutilization of invasive testing when not paired with functional information | Requires CCTA; Currently not as well known as other tests |
Advantages1, 2-6 | Accessible; high specificity; standard of care | Accessible; no radiation | Better long-term outcomes than usual care testing; lower radiation; provides anatomic data | More accurate than other non-invasive tests; provides anatomic and functional information; lower radiation; single patient visit |
* Diagnostic performance of SPECT, CCTA and FFRCT evaluated in a head-to-head comparison for the identification of ischemia.
| SPECT | Stress Echo | Coronary CTA | HeartFlow Analysis |
| HeartFlow Analysis | |
|---|---|
Common Questions |
|
| Stress Echo | |
|---|---|
Common Questions |
|
| Coronary CTA | |
|---|---|
Common Questions |
|
| SPECT | |
|---|---|
Common Questions |
|
Does my patient have CAD? | X | |||
Do the vessels have plaque? | ||||
Where are the coronary artery specific stenoses? | ||||
Is there possible ischemia? | X | |||
What are the lesion-specific functional limitations? | ||||
Which vessels may benefit from PCI/CABG/OMT? | ||||
Is prognostic information provided? | X |
Does my patient have CAD? | X | |||
Do the vessels have plaque? | ||||
Where are the coronary artery specific stenoses? | ||||
Is there possible ischemia? | X | |||
What are the lesion-specific functional limitations? | ||||
Which vessels may benefit from PCI/CABG/OMT? | ||||
Is prognostic information provided? | X |
Does my patient have CAD? | X | |||
Do the vessels have plaque? | X | |||
Where are the coronary artery specific stenoses? | X | |||
Is there possible ischemia? | ||||
What are the lesion-specific functional limitations? | ||||
Which vessels may benefit from PCI/CABG/OMT? | ||||
Is prognostic information provided? | X |
Does my patient have CAD? | X | |||
Do the vessels have plaque? | X | |||
Where are the coronary artery specific stenoses? | X | |||
Is there possible ischemia? | X | |||
What are the lesion-specific functional limitations? | X | |||
Which vessels may benefit from PCI/CABG/OMT? | X | |||
Is prognostic information provided? | X |
Diagnostic Performance* |
|
Disadvantages1, 2-6 | Low sensitivity; high rate of false negatives; higher radiation exposure; lacks anatomic data |
Advantages1, 2-6 | Accessible; high specificity; standard of care |
Diagnostic Performance* |
|
Disadvantages1, 2-6 | Often requires additional testing; lacks anatomic data |
Advantages1, 2-6 | Accessible; no radiation |
Diagnostic Performance* |
|
Disadvantages1, 2-6 | High sensitivity can lead to overutilization of invasive testing when not paired with functional information |
Advantages1, 2-6 | Better long-term outcomes than usual care testing; lower radiation; provides anatomic data |
Diagnostic Performance* |
|
Disadvantages1, 2-6 | Requires CCTA; Currently not as well known as other tests |
Advantages1, 2-6 | More accurate than other non-invasive tests; provides anatomic and functional information; lower radiation; single patient visit |
Click to expand
Click to collapse
Click to expand
* Diagnostic performance of SPECT, CCTA and FFRCT evaluated in a head-to-head comparison for the identification of ischemia.
Click to collapse
How do patients benefit?
HeartFlow addresses the current gaps in traditional diagnostic testing – where patients may be misdiagnosed due to inaccurate test results.1,2
SEE PATIENT CASES
How do patients benefit?
HeartFlow addresses the current gaps in traditional diagnostic testing – where patients may be misdiagnosed due to inaccurate test results.1,2
SEE PATIENT CASES
Frequently asked questions
How accurate is the HeartFlow FFTCT Analysis Pathway?
The pathway provides the highest diagnostic performance available from a non-invasive test to help identify functional disease.1,2 This pathway leads to targeted treatment plans and a more streamlined patient experience.
How can I best incorporate HeartFlow into my practice?
Physicians can use the HeartFlow Analysis for any clinically stable symptomatic patient with CAD. The pathway requires access to a standard CT scanner and an institution that offers the HeartFlow Analysis. Find a center near you using our finder tool or contact your local HeartFlow representative.
How quickly will I get the analysis?
Within hours, physicians can receive the HeartFlow Analysis, which is available on desktop and mobile.
How will my patients benefit?
HeartFlow offers a streamlined workflow that reduces unnecessary invasive testing and radiation exposure, and provides more accurate information about their condition compared to other non-invasive cardiac tests.1,2,3,4 The highly visual, color-coded model resonates well with patients and can help increase adherence to treatment plans.
Frequently asked questions
How accurate is the HeartFlow FFTCT Analysis Pathway?
The pathway provides the highest diagnostic performance available from a non-invasive test to help identify functional disease.1,2 This pathway leads to targeted treatment plans and a more streamlined patient experience.
How can I best incorporate HeartFlow into my practice?
Physicians can use the HeartFlow Analysis for any clinically stable symptomatic patient with CAD. The pathway requires access to a standard CT scanner and an institution that offers the HeartFlow Analysis. Find a center near you using our finder tool or contact your local HeartFlow representative.
How quickly will I get the analysis?
Within hours, physicians can receive the HeartFlow Analysis, which is available on desktop and mobile.
How will my patients benefit?
HeartFlow offers a streamlined workflow that reduces unnecessary invasive testing and radiation exposure, and provides more accurate information about their condition compared to other non-invasive cardiac tests.1,2,3,4 The highly visual, color-coded model resonates well with patients and can help increase adherence to treatment plans.
Additional Resources
- Preview the HeartFlow Analysis
- Find HeartFlow Near You
- Download the Patient Brochure
Contact Us
REFERENCES
- Driessen, et al. J Am Coll Cardiol 2019; Norgaard, et al, Euro J Radiol 2015.
- Melikian, et al. JACC: Cardiovasc Interv 2010; Jung, et al. Euro Heart J 2008. Koo, et al. J Am Coll; Cardiol 2011. Min, et al. JAMA 2012. Norgaard, et al. J Am Coll Cardiol 2014.
- Patel, et al. J Am Coll Cardiol 2019.
- Stocker, et al. Euro Heart J 2018.
- Curzen, N.P., et al., J Am Coll Cardiol 2016. Newby D.E., et al. N Engl J Med 2018.
- Danad, et al., Euro Heart J 2017.
Campbell Rogers, M.D., F.A.C.C.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
